Modern challenges in the NASH clinical landscape have not diminished, but we have gained valuable, experience-based insight and extensive data on screening, recruitment, and dropout to deliver more efficient and expedited trials.
For investigator sites encountering challenges in sample collection, our Patient Service Centers offer an attractive solution. Staffed with highly trained phlebotomists, our PSCs deliver the same level of quality and consistency in results.
AACC 2022 -- Collection of 24-hr urine specimens can be challenging, especially if the urine needs to be collected using a splitter device to collect two different sample types on the same collection.
AACC 2022 -- Quality Control (QC) testing frequency is based on a number of factors such as analytical stability, error tolerance without impacting results, testing volume, etc. Less than optimal frequency can result in erroneous results, which could lead to inappropriate clinical interventions.
AACC 2022 -- Vitamin B12 is necessary for many processes in the body and is a cofactor in methylmalonic acid (MMA) metabolism. Vitamin B12 deficiency may present with few symptoms, however chronic deficiency may lead to macrocytic anemia, peripheral nerve damage and memory impairment.
Welcome to the July 2022 Labcorp Drug Development Decentralized Clinical Trial (DCT) blog. This month, we are going to review our recent presence at several important industry events and provide you with links to a new case study and a just-released video about our snapClinical® technology platform.
An idiotype is a unique antigen-binding site in an antibody and is made up of several epitopes in the variable region. Antibodies raised against the idiotype of a given antibody are called anti-idiotypic antibodies or commonly anti-Ids.
We recently spoke with Daniel Sikkema, executive director of global immunochemistry at Labcorp, regarding bioanalytical support for cell and gene therapy modalities.
Oncology trials are often multisite, multicountry large- scale endeavors, requiring collection of a wide range of data from participants. Traditionally, oncology trials have only been carried out at specialist hospitals with the infrastructure to support patients receiving experimental treatments.
